Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß"), today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 3:30 p.m. Eastern time.
馬薩諸塞州列剋星敦，2024年11月6日（環球社會新聞） - 生物製藥公司科瑞斯療法公司（"Keros"）（納斯達克：KROS），一家臨床階段生物製藥公司，專注於發現、開發和商業化治療範圍廣泛的與轉化生長因子-beta（"TGF-ß"）信號傳導異常相關的疾病患者的新型治療方法，今日宣佈，Keros主席兼首席執行官Jasbir S. Seehra博士將於2024年11月13日週三下午3:30參加古根海姆醫療創新大會的爐邊聊天演講。
A live audio webcast of the fireside chat presentation will be available at and an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of the event.
爐邊聊天演講的現場音頻網絡直播將在網址處提供，活動結束後的90天內，演講的存檔回放將可在Keros網站的投資者部分獲取。
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Keros' second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
關於Keros Therapeutics，Inc.
Keros是一家專注於開發和商業化新型治療藥物，以治療與TGF-ß蛋白家族信號傳導異常相關的一系列患者疾病的臨床階段生物製藥公司。Keros在理解TGF-ß蛋白家族的作用方面處於領先地位，它們是多種組織的生長、修復和維持的主要調節因子，包括血液、骨骼、骨骼肌肉、脂肪和心臟組織。通過利用這種理解，Keros已經發現並正在開發可能爲患者提供有意義並可能具有疾病修正作用的蛋白質治療方法。Keros的主要產品候選藥elritercept（KER-050）正在開發用於治療骨髓增生異常綜合徵和骨髓纖維化患者的低血細胞計數，包括貧血和血小板減少症。Keros的第二個產品候選藥cibotercept（KER-012）正在用於治療肺動脈高壓和心血管疾病。Keros的第三個產品候選藥KER-065正在用於肥胖和神經肌肉疾病的治療。
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
投資者聯繫人：
Justin Frantz
jfrantz@kerostx.com
617-221-6042
譯文內容由第三人軟體翻譯。
